Nurix Therapeutics, Inc. reported earnings results for the second quarter and six months ended May 31, 2024. For the second quarter, the company reported revenue was USD 12.09 million compared to USD 30.68 million a year ago. Net loss was USD 44.55 million compared to USD 24.28 million a year ago. Basic loss per share from continuing operations was USD 0.71 compared to USD 0.45 a year ago.
For the six months, revenue was USD 28.68 million compared to USD 43.36 million a year ago. Net loss was USD 86.06 million compared to USD 65.01 million a year ago. Basic loss per share from continuing operations was USD 1.47 compared to USD 1.2 a year ago.